RECARDIO has an experienced management team with longtime and significant experience and reputation in drug development, cardiology, the biotech industry and is complemented by exclusive boards.
Darrell Nix, PH.D.
Chief Scientific Officer
Darrell Nix’s responsibilities span from drug development to scientific affairs management.
Darrell has specialized in ADME issues with small molecule development and large molecule PK/PD modeling. Prior to this he was a key contributor to the successful marketing registration of several compounds as well as compounds in cardiovascular and metabolic diseases and has more than 25 years of drug discovery and development.
Darrell has a bachelors degree in analytical chemistry and a graduate degree in pharmacology and trained in the US FDA’s Clinical Pharmacology Fellowship program.
Frank Ahmann, MBA
Chief Operating Officer
Frank Ahmann’s responsibilities cover corporate business development including US clinical development and he is also in charge of US operations.
Frank was before President and CEO of another company in the regenerative cardiac area, where he led the development from concept to proof of clinical efficacy. Prior to that, he led three other biomedical start-ups and spent 10 years in the pharmaceutical industry in US and European operations.
Frank holds a BBA with Honors from the University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.
Dr. Stephan Henauer, MD
Chief Medical Officer
Stephan Henauer is responsible for clinical operations and medical affairs.
Stephan is a clinical drug development expert with more then 30 years biopharmaceutical industry experience. He held senior management and international leadership roles in clinical development, medical & regulatory affairs, and general management.
Stephan received his medical degree at the University of Zürich, was subsequently awarded a Fellowship in Medicine and Clinical Pharmacology at Stanford University, and specialized in Pharmaceutical Medicine FMH.